



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



C16 α -Glucosylceramide (d18:1/16:0) (synthetic)

Item No. 40274

CAS Registry No.: 74365-77-8
Formal Name: N-[(1S,2R,3E)-1-[(β -D-glucopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-hexadecanamide
Synonyms: N- ω -CD₃-Hexadecanoyl-glucosylpsychosine, GluCer(d18:1/16:0)
MF: C₄₀H₇₇NO₈
FW: 700.0
Purity: \geq 98%
Supplied as: A solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

C16 α -Glucosylceramide (d18:1/16:0) (synthetic) is supplied as a solid. A stock solution may be made by dissolving the C16 α -glucosylceramide (d18:1/16:0) (synthetic) in the solvent of choice, which should be purged with an inert gas. C16 α -Glucosylceramide (d18:1/16:0) (synthetic) is sparingly soluble (1-10 mg/ml) in the organic solvent methanol.

Description

C16 α -Glucosylceramide is a bioactive glycosphingolipid.^{1,2} It is a precursor in the synthesis of C16 lactosylceramide (Item No. 24352) that is formed *via* metabolism of C16 ceramide (Item No. 10681) by glucosylceramide synthase.³ Inhalation of C16 glucosylceramide reduces lung colonization by *P. aeruginosa* and increases survival in a mouse model of cystic fibrosis.¹ C16 Glucosylceramide levels are elevated in the plasma of Parkinson's disease patients with cognitive impairments.² This product is fully synthetic and has no variations in the fatty acyl chain or sphingoid backbone.

References

1. Kovacic, B., Sehl, C., Wilker, B., *et al.* Glucosylceramide critically contributes to the host defense of cystic fibrosis lungs. *Cell Physiol. Biochem.* **41(3)**, 1208-1218 (2017).
2. Mielke, M.M., Maetzler, W., Haughey, N.J., *et al.* Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: A pilot study. *PLoS One* **8(9)**, e73094 (2013).
3. Holland, W.L. and Summers, S.A. Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism. *Endocr. Rev.* **29(4)**, 381-402 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/14/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM